European Neuropsychopharmacology
Volume 19, Issue 9 , Pages 611-628 , September 2009

Molecular tools for assessing human depression by positron emission tomography

  • Donald F. Smith

      Affiliations

    • Center for Psychiatric Research, Psychiatric Hospital of Aarhus University, 8240 Risskov, Denmark
    • Corresponding Author InformationCorresponding author.
    • ,
  • Steen Jakobsen

      Affiliations

    • PET Center, Aarhus University Hospital, 8000 Aarhus C, Denmark

Received 22 October 2008 ,Revised 11 March 2009 ,Accepted 2 April 2009.

References 

  1. Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V. “Serotonin depression”—a biochemical subgroup within the affective disorders?. Science. 1976;191:478–480
  2. Beck AT, Ward C, Mendelson M. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:571
  3. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006;7:137–151
  4. Bhagwagar Z, Montgomery AJ, Grasby PM, Cowen PJ. Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. Biol. Psychiatry. 2003;54:890–895
  5. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry. 2004;9:386–392
  6. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am. J. Psychiatry. 2006;163:1580–1587
  7. Bhagwagar Z, Murthy N, Selvaraj S, Hinz R, Taylor M, Fancy S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am. J. Psychiatry. 2007;164:1858–1865
  8. Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776–1780
  9. Bragulat V, Paillere-Martinot ML, Artiges E, Frouin V, Poline JB, Martinot JL. Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res. 2007;154:115–124
  10. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry. 2006;63:741–747
  11. Cannon DM, Ichise M, Fromm SJ, Nugent AC, Rollis D, Gandhi SK, et al. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol. Psychiatry. 2006;60:207–217
  12. Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol. Psychiatry. 2007;62:870–877
  13. Cannon DM, Klaver JM, Peck SA, Rallis-Voak D, Erickson K, Drevets WC. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [(11)C]NNC-112. Neuropsychopharmacology. 2007;34:1277–1287
  14. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry. 1990;47:411–418
  15. Dougherty DD, Bonab AA, Ottowitz WE, Livni E, Alpert NM, Rauch SL, et al. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress. Anxiety. 2006;23:175–177
  16. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 2002;12:527–544
  17. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 2007;34:865–877
  18. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry. 2007;64:327–337
  19. Fitzgerald PB, Oxley TJ, Laird AR, Kulkarni J, Egan GF, Daskalakis ZJ. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Res. 2006;148:33–45
  20. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg Psychiatry. 1960;12:62
  21. Hesse S, Barthel H, Schwarz J, Sabri O, Muller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2004;28:547–563
  22. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry. 2002;17(Suppl 3):294–299
  23. Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala H, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int. J. Neuropsychopharmacol. 2008;11:465–476
  24. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 2003;23:1096–1112
  25. Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, et al. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur. J. Neurosci. 2004;20:803–810
  26. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder—implications for psychopharmacology. World J. Biol. Psychiatry. 2002;3:133–146
  27. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894–902
  28. Kuroda Y, Motohashi N, Ito H, Ito S, Takano A, Nishikawa T, et al. Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression. J. Affect. Disord. 2006;95:35–42
  29. Lammertsma AA. Radioligand studies: imaging and quantitative analysis. Eur. Neuropsychopharmacol. 2002;12:513–516
  30. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb. Blood Flow Metab. 2000;20:423–451
  31. Laruelle M, Slifstein M, Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods. 2002;27:287–299
  32. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990;10:740–747
  33. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro. Endocrinol. Lett. 2008;29:287–291
  34. Mayberg HS. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin. N. Am. 2003;13:805–815
  35. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In:  Meltzer HY editors. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987;p. 513–526
  36. Meltzer CC, Price JC, Mathis CA, Butters MA, Ziolko SK, Moses-Kolko E, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004;29:2258–2265
  37. Messa C, Colombo C, Moresco RM, Gobbo C, Galli L, Lucignani G, et al. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl). 2003;167:72–78
  38. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 2007;32:86–102
  39. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am. J. Psychiatry. 2003;160:90–99
  40. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry. 2004;61:1271–1279
  41. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry. 2004;161:826–835
  42. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry. 2006;63:1209–1216
  43. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NP, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am. J. Psychiatry. 2006;163:1594–1602
  44. Mickey BJ, Ducci F, Hodgkinson CA, Langenecker SA, Goldman D, Zubieta JK. Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J. Neurosci. 2008;28:11354–11359
  45. Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J. Psychiatr. Res. 2008;42:1137–1142
  46. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol. Psychiatry. 2004;55:217–224
  47. Montgomery AJ, Stokes P, Kitamura Y, Grasby PM. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J. Affect. Disord. 2007;101:113–122
  48. Moses-Kolko EL, Price JC, Thase ME, Meltzer CC, Kupfer DJ, Mathis CA, et al. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse. 2007;61:523–530
  49. Oquendo MA, Hastings RS, Huang YY, Simpson N, Ogden RT, Hu XZ, et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch. Gen. Psychiatry. 2007;64:201–208
  50. Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am. J. Psychiatry. 2006;163:52–58
  51. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry. 2006;59:106–113
  52. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 1983;3:1–7
  53. Praschak-Rieder N, Hussey D, Wilson AA, Carella A, Lee M, Dunn E, et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study. Biol. Psychiatry. 2004;56:587–591
  54. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl). 1977;53:309–314
  55. Ravnkilde B, Videbech P, Clemmensen K, Egander A, Rasmussen NA, Gjedde A, et al. The Danish PET/depression project: cognitive function and regional cerebral blood flow. Acta Psychiatr. Scand. 2003;108:32–40
  56. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol. Psychiatry. 2008;13:606–613
  57. Reivich M, Amsterdam JD, Brunswick DJ, Shiue CY. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J. Affect. Disord. 2004;82:321–327
  58. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–1322
  59. Rosa-Neto P, Diksic M, Okazawa H, Leyton M, Ghadirian N, Mzengeza S, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch. Gen. Psychiatry. 2004;61:556–563
  60. Schildkraut JJ, Kety SS. Biogenic amines and emotion. Science. 1967;156:21–30
  61. Schildkraut JJ, Davis JM, Klerman GL. Biochemistry of depressions. In: Psychopharmacology: A Review of Progress, 1957–1967. Bethesda, Maryland: National Institute of Mental Health; 1968;p. 625–648
  62. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT(2A) receptors in midlife than in late life. Am. J. Psychiatry. 2002;159:430–435
  63. Sheline YI, Mintun MA, Barch DM, Wilkins C, Snyder AZ, Moerlein SM. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology. 2004;29:2235–2241
  64. Smith GS, Koppel J, Goldberg S. Applications of neuroreceptor imaging to psychiatry research. Psychopharmacol. Bull. 2003;37:26–65
  65. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999;22:521–527
  66. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 2003;37:357–373
  67. Sullivan GM, Oquendo MA, Simpson N, van Heertum RL, Mann JJ, Parsey RV. Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety. Biol. Psychiatry. 2005;58:947–954
  68. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J. Nucl. Med. 1994;35:955–963
  69. Tanis KQ, Duman RS. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann. Med. 2007;1–14
  70. Theodore WH, Hasler G, Giovacchini G, Kelley K, Reeves-Tyer P, Herscovitch P, et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia. 2007;48:1526–1530
  71. Videbech P, Ravnkilde B, Pedersen TH, Hartvig H, Egander A, Clemmensen K, et al. The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis. Acta Psychiatr. Scand. 2002;106:35–44
  72. Voineskos AN, Wilson AA, Boovariwala A, Sagrati S, Houle S, Rusjan P, et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl). 2007;193:539–545

PII: S0924-977X(09)00099-6

doi: 10.1016/j.euroneuro.2009.04.005

European Neuropsychopharmacology
Volume 19, Issue 9 , Pages 611-628 , September 2009

Article Tools

* Image Usage & Resolution